Clinical trial · Observational
Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent
NCT01303692CI-TRIAL-00016617completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- A
- description
- Total of 250 prostate cancer patients receiving GnRH agonist
- label
- B
- description
- Total of 250 prostate cancer patients receiving GnRH agonist plus anti-androgen agent
Primary outcomes (2)
- measure
- comparison of bone density before and after hormone therapy
- timeFrame
- 1 year
- measure
- comparison of bone density between GnRH agonist alone vs. CAB group
- timeFrame
- 1 year
Secondary outcomes (3)
- measure
- correlation between osteoporosis risk factors such as age, weight, history of smoke, history of alcohol and bone density value
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Korean prostate cancer over 50 years old with pathological confirmation * Patients receiving GnRH antagonist or GnRH agonist plus anti- androgen combination within 6 months since starting. * Patients measured bone density level before starting to receive hormone therapies above. Exclusion Criteria: * Patients who are treated other anti-osteoporosis drugs and who are treated bisphosphate due to BMD T score below -3.0. * Patients who are hard to be analysed by attach to other bone disease. * Patients who are hard to be analysed by limitation of chart record according to investigators'discretion.
References
Publications (1)
- DERIVEDKim SH, Joung JY, Kim S, Rha KH, Kim HG, Kwak C, Lee JY, Jeon SS, Hong SK, Jeong H, Jo MK, You D, Jeong IG, Hong JH, Kim CS. Comparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: A 12 month-prospective observational study. Sci Rep. 2017 Mar 6;7:39562. doi: 10.1038/srep39562. PMID 28262724